FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84034
Company■ Unclear/unknown
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A not-yet-recruiting Phase 3 gastric cancer trial is early-stage and years from revenue.
Early oncology trial, long timeline to impact
CATALYST TO WATCH
Enrollment start and interim data
MAIN RISK
Trial may fail or be delayed
FULL DISPATCH
Sponsor: AstraZeneca; Status: Not Yet Recruiting; Conditions: Gastric, Esophagogastric Junction; Interventions: FLOT Chemotherapy, Durvalumab; Enrollment: 140 (estimated); First posted: 2026-10-16; NCT: NCT07877818
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTAstraZeneca · AZN
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
Withings BodyScan 2 Named One of TIME's Best Inventions of 20262026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors2026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.